MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- BH.IMMUN&BIO (pharmaceuticals)
- Latest 8 Quarter Result
BH.IMMUN&BIO Quarterly Results (BHIB)
Here are the latest quarterly results of BH.IMMUN&BIO. For more details, see the BH.IMMUN&BIO financial fact sheet and BH.IMMUN&BIO share price and chart. For a sector overview, read our pharmaceuticals sector report.
BH.IMMUN&BIO Quarterly Results
| No. of Mths Qtr. Ending |
3
Mar-19* |
3
Jun-19* |
3
Sep-19* |
3
Jun-20* |
3
Sep-20* |
3
Dec-20* |
3
Jun-21* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 706 | 70 | 81 | 192 | 254 | 252 | 142 | |
| Other income | Rs m | 21 | 18 | 2 | -6 | 1 | 12 | 2 | |
| Turnover | Rs m | 727 | 88 | 83 | 186 | 255 | 264 | 145 | |
| Expenses | Rs m | 749 | 127 | 148 | 185 | 299 | 275 | 132 | |
| Gross profit | Rs m | -43 | -57 | -67 | 6 | -45 | -23 | 10 | |
| Depreciation | Rs m | 0 | 2 | 1 | 1 | 1 | 1 | 1 | |
| Interest | Rs m | 9 | 9 | 12 | 11 | 12 | 13 | 12 | |
| Profit before tax | Rs m | -31 | -50 | -78 | -11 | -56 | -24 | 1 | |
| Tax | Rs m | -9 | -15 | -22 | -3 | -17 | -5 | -19 | |
| Profit after tax | Rs m | -22 | -35 | -57 | -8 | -39 | -19 | 19 | |
| Gross profit margin | % | -6.1 | -82.0 | -82.6 | 3.3 | -17.7 | -9.0 | 7.3 | |
| Effective tax rate | % | 28.4 | 30.8 | 27.7 | 28.9 | 30.8 | 22.0 | -2,504.1 | |
| Net profit margin | % | -3.2 | -49.4 | -69.8 | -4.1 | -15.2 | -7.5 | 13.6 | |
| Diluted EPS | Rs | -0.5 | -0.8 | -1.3 | -0.2 | -0.9 | -0.4 | 0.4 | |
| Diluted EPS (TTM) | Rs | NA | NA | NA | -2.8 | -3.2 | -2.8 | -1.1 | |
 Subscriber Feature |
|||||||||
Interim results exclude extraordinary / exceptional items
More Pharmaceuticals Company Quarterly Results: MAKERS LAB. KAMRON LABORATORIES DISHMAN CARBOGEN AMCIS NURECA JUBILANT INDUSTRIES
Compare BH.IMMUN&BIO With: MAKERS LAB. KAMRON LABORATORIES DISHMAN CARBOGEN AMCIS NURECA JUBILANT INDUSTRIES
Today's Market
Policybazaar's Mega IPO, Glenmark's New Deal for Covid Treatment, and Buzzing Stocks Today(Pre-Open)
Indian share markets ended on a positive note yesterday. Benchmark indices rallied after tracking positive cues across global markets and helped by gains in realty and auto stocks.
Views on news
Windlas Biotech IPO to Hit the Market on 4 August. Key Points to Know (Views On News)
Jul 31, 2021Windlas Biotech IPO to open for subscription next week. Price band fixed at Rs 448-460.
Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates (Views On News)
Jul 30, 2021Here's a rundown on Sun Pharma's June quarter results.
Glenmark Life Sciences IPO Opens Tomorrow: Few Points to Know Before Applying (Views On News)
Jul 26, 2021All you need to know about the IPO of Glenmark Life Sciences.
Why Did Pharma Stocks Surge? (Views On News)
Jul 17, 2021A look into the factors contributing to the rally in pharma stocks.
Bajaj Healthcare Rallies 11% on DRDO Nod to Manufacture Oral Covid Drug (Views On News)
Jul 8, 2021Bajaj Healthcare has more than doubled investors' wealth in the year 2021 so far. The counter has delivered over 240% return in the last one year.
More Views on NewsMost Popular
Make Startup Profits from Bluechip Stocks (Profit Hunter)
Jul 21, 2021A 166-bagger stock can deliver even more gains in this decade.
These Are the Best Stocks to Own (Fast Profits Daily)
Jul 22, 2021Find out what I think are the best kind on stocks to own in the market.
Cash the Crash in Gas Prices (Fast Profits Daily)
Jul 21, 2021Get ready to profit from the coming crash in the price of natural gas.
A Trading Hack to Multiply Profits (Fast Profits Daily)
Jul 23, 2021Use this trading hack and get a big boost in your trading profits.
How to Pick Momentum Stocks (Fast Profits Daily)
Jul 26, 2021Use my trading momentum strategy to increase your trading profits.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
BH.IMMUN&BIO SHARE PRICE
Aug 2, 2021 (Close)
TRACK BH.IMMUN&BIO
- Track your investment in BH.IMMUN&BIO with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON BH.IMMUN&BIO
BH.IMMUN&BIO - ACTAVIS COMPARISON
COMPARE BH.IMMUN&BIO WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
FOLLOW
APP
EQUITYMASTER SUPPORTS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.